Enhanced pre-eclampsia screening utilizing biomarkers was first introduced in early 2000 by Fetal Medicine Foundation (FMF). Evidence to prove added value of biomarkers to enhance traditional screening models has evolved since. In this webinar, the father of FMF pre-eclampsia prediction models, Professor Kypros Nicolaides provides his insights to current developments and future prospects in this field.
As one remarkable milestone in the journey from invention to implementation of pre-eclampsia screening is the first recommendation in public health to offer preterm pre-eclampsia screening to all women in Ontario, Canada. Professor Nanette Okun from University of Toronto will share her experiences in the creation of the recommendation to encourage others through this positive progress.
SPEAKERS
Published 1,603 peer-review papers in Scientific Journals. His h-index is 192 (highest of all obstetricians and gynaecologists in the world) and his work has been cited more than 135 thousand times.
Edited or wrote 14 books. Introduced internet-based courses for health care professionals and patients
Supervised 66 doctors to undertake research leading to postgraduate qualifications and has provided training in Fetal Medicine to 600 doctors from 50 countries.
Dr Nan Okun is the head of the division of Maternal Fetal Medicine at Sunnybrook Hospital, Professor in the Department of Obstetrics and Gynecology at the University of Toronto and co-medical director of Prenatal Screening Ontario (prenatalscreeningontario.ca). She has had a longstanding interest in prenatal screening and diagnosis, with a focus on expanding population-based prenatal screening beyond aneuploidy.
A significant milestone in the journey from invention to implementation of preterm pre-eclampsia screening is a recommendation for publicly funding a population-wide first-trimester screening program using the algorithm developed by the Fetal Medicine Foundation for all pregnancies in Ontario, Canada. Professor Nan Okun from University of Toronto will share experience in the creation of the recommendation and planned next steps; to encourage a broader conversation towards implementation internationally.
Re-watch:
Share
Company
Nova Natura UAB
Kaštonų g. 56, Giraitės k, LT-54310, Kaunas, Lithuania